Mark Pegram, MD
Although tremendous advances have been made in HER2-positive breast cancer, Mark Pegram, MD, says researchers are just getting started.
at the meeting, Pegram, associate director for clinical research and director of the breast oncology program at Stanford Women’s Cancer Center, discussed emerging treatments in HER2-positive breast cancer and his vision for the future of the field.
OncLive: Please provide an overview of your presentation.
Right now, based on level 1 evidence, we have good data to support the use of pertuzumab (Perjeta) in combination with trastuzumab (Herceptin) and chemotherapy in the first-line setting. That’s usually followed by T-DM1 (ado-trastuzumab emtansine; Kadcyla) in the second-line, based on the EMILIA pivotal trial, which was published in the New England Journal of Medicine
just a few years ago. There was also a recent publication with the updated overall survival analysis, which remains significant.
... to read the full story